STATINS IN PREVENTION OF ISCHEMIC STROKE
https://doi.org/10.20996/1819-6446-2013-9-4-409-416
Abstract
The evidence base of statin therapy in primary and secondary prevention of ischemic stroke is surveyed. Results of classical trails with statins in ischemic stroke prevention as well as results of meta-analyses are discussed.
About the Authors
A. V. Susekov
Russian Cardiology Research and Production Complex, Moscow
Russian Federation
Russian Federation
A. B. Blohin
Out-patient Clinic №3, Administrative Department of the President of the Russian Federation, Moscow
Russian Federation
Russian Federation
Z. G. Luginova
Russian Cardiology Research and Production Complex, Moscow
Russian Federation
Russian Federation
E. J. Soloveva
Russian Cardiology Research and Production Complex, Moscow
Russian Federation
Russian Federation
N. V. Maltseva
The Central Out-patient Clinic №1, Ministry of the Interior of Russia, Moscow
Russian Federation
Russian Federation
O. E. Tarasova
Russian Federation
V. V. Kuharchuk
Russian Cardiology Research and Production Complex, Moscow
Russian Federation
Russian Federation
References
1. Go AS, Mozaffarian D, Roger VL et al. Executive Summary: Heart Disease and Stroke Statistics-2013 Update: A Report From the American Heart Association. Circulation 2013; 127(1):143-52.
2. Kuklina EV, Tong X, George MG et al. Epidemiology and prevention of stroke: a worldwide perspective. Expert Rev Neurother 2012;12(2):199-208.
3. Shalnova S.A., Deyev A.D. Mortality tendencies in Russia in the XXI-st century beginning (according to the official statistics). Cardiovascular Therapy and Prophylaxis 2011; 10 (6): 5-10. Russian (Шальнова С.А., Деев А.Д. Тенденции смертности в России в начале XXI века (по данным официальной статистики). Кардиоваскулярная Терапия и Профилактика 2011; 10(6): 5-10).
4. Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internalcarotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 2000;342:1693-700.
5. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
6. O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376(9735):112-23.
7. Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009;27(5):947-54.
8. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
9. Shepherd J, Cobbe SM, Isles CG et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-7.
10. Everett BM, Glynn RJ, MacFadyen JC et al. Rosuvastatin in the ptrevention of stroke among men and women with elevated levels of C-reactive protein: justification for the use of satins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation 2010; 121(10: 143-50.
11. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
12. Sacks FN, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Engl J Med 1996; 335: 1001-9.
13. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;4:220-8.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial. Lancet 2002; 360:7-22.
15. Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease Heart Protection Study Collaborative Group. Lancet 2004;363:757-67.
16. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Eng J Med 1998; 339: 1349-57.
17. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711-8.
18. Amarenco P, Bogousslavsky J, Callahan A et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355(6):549-59.
19. LaRosa JC, Grundy SM, Waters DD et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288(23):2998-3007.
21. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and сlinical results. Trends Mol Med 2008;14(1):37-44.
22. Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92(12):1379-83.
23. Ozaydin M, Varol E, Aslan SM et al. Еffect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97(10):1490-3.
24. Loffredo L, Angelico F, Perri L, Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord 2012;12:107.
25. Wolozin B, Wang SW, Li NC et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20.
26. Wang Q, Yan J, Chen X et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011;230(1):27-34.
27. Arnaud C, Veillard NR, Mach F et al. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005:5 (2): 127-34.
28. Thongtang N, Diffenderfer MR, Ooi EM et al. Effects of atorvastatin on human C-reactive protein metabolism. Atherosclerosis 2013;226(2):466-70.
29. Tsai NW, Lee LH, Huang CR et al. The association of statin therapy and high-sensitivity C-reactive protein level for predicting clinical outcome in acute non-cardioembolic ischemic stroke. Clin Chim Acta 2012;413(23-24):1861-5.
30. Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment increases сollagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103(7):926-33.
31. Goldstein LB, Amarenco P, Szarek M et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70(24 Pt 2):2364-70.
32. Amarenco P. Benavente O, Goldstein L et al. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke 2009;40:1405-9.
33. Amarenco P, Goldstein L, Callahan A et al. Baseline blood pressure, low-density lipoproteins and triglycerides and the risk of vascular vents in the Stroke Prevention by Aggressive reduction in Cholesterol levels (SPARCL) trial. Atherosclerosis 2009; 204:515-20.
34. Sillesen H, Amarenco P, Hennerichi M et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. A secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholresterol Levels (SPARCL) trial. Stroke 2008;39:3297-3302.
35. Callahan A, Amarenco P, Goldstein LB et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol 2011; 68(10):1245-51.
36. Amarenco P, Goldstein LB, Sillesen H et al. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2010;41(3):426-30.
37. Hebert P, Gaziano JM, Chan KS et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278(4):313-21.
38. Taylor F, Huffman, MD , Bacedo AF et al. Statins for the primary prevention of cardiovascular disease. Cocharane Database Syst Rev 2013;1:CD004816.
39. Tonelli M, Lloyd A, Clement F et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011;183(16):E1189-202.
40. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9433):1267-78.
41. Baigent C, Blackwell L, Emberson J et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670-81.
42. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581-90.
43. deVries FM, Denig P, Pouwels KB et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012; 72(18):2365-73.
44. Ni Chroinin D, Asplund K, Asberg S et al. Statin Therapy and Outcome After Ischemic Stroke: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials. Stroke 2013; 44(2):448-56.
45. Cannon C P, Steinberg B A , Murphy S A et al. Meta-analysis of cardiovascular outcomes trials com- paring intensive versus moderate statin therapy. Am J Cardiol 2006;48(3): 438-45.
46. Cannon C, Braunwald E, McCabe C H et al. Intensive versus Moderate Lipid-lowering with statins after Acute Coronary Syndromes. N Engl J Med 2004;350:1495-504.
47. McKiney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012;43(8):2149-56.
48. Catapano A., Reiner Z, De Backer G, et al. EAS/EAS Guidelines for the management of dyslipidemias. The Task Force for the management of dyslipideamias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217S:S1-S44.
49. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2012;19(4):585-667.
50. Furie K, Kasner SE, Adams RJ et al. Guidelines for prevention of stroke in patients with stroke or transient Ischemic attack .A Guideline for Healthcare professionals from the American Heart Association/American Stroke association. Stroke 2011;42:227-76.
Review
For citations:
Susekov A.V., Blohin A.B., Luginova Z.G., Soloveva E.J., Maltseva N.V., Tarasova O.E., Kuharchuk V.V. STATINS IN PREVENTION OF ISCHEMIC STROKE. Rational Pharmacotherapy in Cardiology. 2013;9(4):409-416. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-4-409-416
Views:
1000
Email this article 